Incyte Corp.

Incyte is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. JAKAFI (ruxolitinib) has been approved for the treatment of patients with intermediate or high-risk myelofibrosis, for the treatment of patients with polycythemia vera, and for the treatment of steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older. The company has also obtained a license to develop and commercialize ICLUSIG (ponatinib) in Europe and other select countries. In the European Union, ICLUSIG is approved for the treatment of adult patients with chronic phase, accelerated phase or blast phase chronic myeloid leukemia.
  • TickerINCY
  • ISINUS45337C1027
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
Valens Research

INCY - Embedded Expectations Analysis - 2021 04 06

Incyte Corporation (INCY:USA) currently trades well below corporate averages relative to UAFRS-based (Uniform) earnings, with an 8.4x Uniform P/E. At these levels, the market is pricing in bearish expectations for the firm, but management is confident about their LIMBER program trials, CITADEL study, and Monjuvi uptake Specifically, management is confident they are seeing good uptake for Monjuvi across their top 100 key accounts, that the number of prescriptions for the treatment of atopic dermatitis has grown significantly in recent years, and that there are a lot of aspects of the LIMBER pr...

Incyte Corp: 1 director sold

A director at Incyte Corp sold 20,000 shares at 81.080USD and the significance rating of the trade was 77/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board me...

Jonathan Moreland

InsiderInsights Daily Ratings Report: February 23, 2021

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

INCYTE loses on its star level and is downgraded to Slightly Positive

The independent financial analyst theScreener just slightly lowered the general evaluation of INCYTE (US), active in the Biotechnology industry. The title has lost a star(s) at the fundamental level and now shows 3 out of 4 stars. Its exposure to market risk remains nonetheless the same and can be still described as defensive. theScreener slightly downgrades the general evaluation to Slightly Positive for the title on account of the lost star(s). As of the analysis date February 9, 2021, the closing price was USD 89.46 and its potential was estimated at USD 107.03.

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Market In “Wait-And-See” Phase We started to see waning upside momentum in the S&P 500 last week with the rising wedge breakdown and 2760 support level violation on Tuesday. Despite this, there was no downside follow through the following day as investors digested a new $484B fiscal relief package. This led to the S&P 500 finding support at 2725-2735 which leads us to where we are now -- testing recent highs. We see waning upside momentum and several aspects continue to suggest the S&P 500 remains vulnerable to a pullback, but the market is simply not breaking down. We believe some near-t...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Incyte Corp: 1 director sold

A director at Incyte Corp sold 20,000 shares at 81.080USD and the significance rating of the trade was 77/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board me...

Valens Research

INCY - Embedded Expectations Analysis - 2021 04 06

Incyte Corporation (INCY:USA) currently trades well below corporate averages relative to UAFRS-based (Uniform) earnings, with an 8.4x Uniform P/E. At these levels, the market is pricing in bearish expectations for the firm, but management is confident about their LIMBER program trials, CITADEL study, and Monjuvi uptake Specifically, management is confident they are seeing good uptake for Monjuvi across their top 100 key accounts, that the number of prescriptions for the treatment of atopic dermatitis has grown significantly in recent years, and that there are a lot of aspects of the LIMBER pr...

Jonathan Moreland

InsiderInsights Daily Ratings Report: February 23, 2021

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Valens Research

Valens Equity Insights and Inflections - 2021 01 19

ASGN is currently valued like it is a struggling staffing company, not that it is focused on staffing in some of the tightest labor markets right now in the midst of the At-Home world and the digitization of business. Markets are expecting UAFRS-based (Uniform) ROA (ROA') to decline by almost half, to lows not seen since emerging from the Great Recession in 2011, with slower growth for the company too. The market is viewing ASGN as a hyper cyclical staffing business, when, thanks to its positioning in areas like AI, machine learning, cloud, cybersecurity, and other tech focused areas, they ar...

Valens Research

INCY - Embedded Expectations Analysis - 2021 01 13

Incyte Corporation (INCY:USA) currently trades near recent averages relative to UAFRS-based (Uniform) earnings, with a 16.7x Uniform P/E. At these levels, the market has bearish expectations for the firm, but management is confident about drug efficacy, their dermatological cream, and patient starts Specifically, management is confident in their ability to improve INCB00928's (ALK2) efficacy and that they will have a partnership in Asia and the rest of the world for their dermatological cream. Furthermore, they are confident that broad access to FGFR testing led to rapid patient adoption and ...

INCYTE loses on its star level and is downgraded to Slightly Positive

The independent financial analyst theScreener just slightly lowered the general evaluation of INCYTE (US), active in the Biotechnology industry. The title has lost a star(s) at the fundamental level and now shows 3 out of 4 stars. Its exposure to market risk remains nonetheless the same and can be still described as defensive. theScreener slightly downgrades the general evaluation to Slightly Positive for the title on account of the lost star(s). As of the analysis date February 9, 2021, the closing price was USD 89.46 and its potential was estimated at USD 107.03.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch